Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300509 | 0.80 | KDM4E (0.76) | KDM4ESMN1; SMN2MAPTRAB9AALDH1A1 | |
| SCHEMBL492339 | 0.76 | MEN1 (0.52) | KDM4ESMN1; SMN2MAPTRAB9AALDH1A1 | |
| SCHEMBL9379820 | 0.76 | RAB9A (0.63) | KDM4ESMN1; SMN2MAPTRAB9AATM | |
| SCHEMBL2848539 | 0.74 | KDM4E (0.59) | KDM4ESMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL14419624 | 0.73 | KDM4E (0.65) | KDM4ESMN1; SMN2MAPTRAB9AALDH1A1 | |
| SCHEMBL6360374 | 0.73 | MAPT (0.52) | KDM4ESMN1; SMN2MAPTRAB9AALDH1A1 | |
| SCHEMBL2848543 | 0.72 | KDM4E (0.64) | KDM4ESMN1; SMN2MAPTATMALDH1A1 | |
| SCHEMBL5273732 | 0.72 | ALDH1A1 (0.62) | SMN1; SMN2MAPTALDH1A1HTTLMNA | |
| SCHEMBL2117044 | 0.71 | GAA (0.71) | KDM4ESMN1; SMN2MAPTRAB9AALDH1A1 | |
| SCHEMBL8784077 | 0.71 | KDM4E (0.55) | KDM4ESMN1; SMN2MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741318-B2 | Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1836205-B1 | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1836205-B1 | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20060135526-A1 | Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135526-A1 | Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA2B | KDM4E 4502/4885SMN1; SMN2 1934/4885MAPT 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.